Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial resul ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Viking Therapeutics, Inc. (VKTX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Viking Therapeutics curr ...

We could be witnessing the birth of a major player in the biotech industry. Five years ago, Viking Therapeutics (VKTX 5.43%) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small drugmakers, and most of those never end up producing the kinds of results or performances investors want to see. However, a lot has changed since: Viking still has no products on the market, but its leading candidates have made exciting clinical progress. That's why its shares soared this year. There is stil ...

Group 1: Market Overview - The biotech sector, particularly in obesity treatments, is identified as one of today's hottest markets, with significant revenue potential and high demand [4][5]. - The obesity drug market is projected to grow rapidly, with Goldman Sachs Research estimating it could increase more than 16-fold to reach $100 billion by the end of the decade [8]. Group 2: Company Profile - Viking Therapeutics - Viking Therapeutics is developing dual GIP/GLP-1 receptor agonists for obesity, with an injectable candidate in phase 2 showing up to a 15% reduction in body weight over 13 weeks, and a pill format entering phase 2 after positive phase 1 results [5][6][10]. - The company has a strong cash position of over $900 million, allowing it to fund the advancement of its programs [10]. Group 3: Competitive Landscape - Demand for weight loss drugs from major players like Eli Lilly and Novo Nordisk has exceeded supply, indicating a market opportunity for additional competitors [7]. - Viking Therapeutics is positioned to potentially be an acquisition target due to its late-stage development of its injectable candidate, which could attract larger pharmaceutical companies [9]. Group 4: Investment Potential - Viking shares are highly reactive to pipeline news, with a notable 120% increase following positive results from its injectable candidate, although the stock has since settled around $60, presenting a buying opportunity [11]. - Continued progress in Viking's weight loss portfolio could lead to significant long-term gains for investors [12].

Company Performance - Viking Therapeutics, Inc. (VKTX) closed at $62.45, reflecting a -0.3% change from the previous day, underperforming the S&P 500's daily loss of 0.21% [1] - Over the past month, shares of Viking Therapeutics have appreciated by 2.98%, outperforming the Medical sector's loss of 3.28% but lagging behind the S&P 500's gain of 5.94% [1] Earnings Forecast - Viking Therapeutics is projected to report earnings of -$0.24 per share, indicating a year-over-year decline of 4.35% [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be monitored, as positive revisions indicate analysts' confidence in the company's performance and profit potential [3] - The Zacks Consensus EPS estimate has decreased by 0.99% over the last 30 days, and Viking Therapeutics currently holds a Zacks Rank of 3 (Hold) [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, ranks in the top 34% of all industries according to the Zacks Industry Rank, indicating a strong position within the sector [6]

Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinicalstage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thy ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $64.96, moving +1.33% from the previous trading session. This change outpaced the S&P 500's 0.9% gain on the day. On the other hand, the Dow registered a gain of 0.81%, and the technology-centric Nasdaq increased by 1.22%. Shares of the company have appreciated by 15.74% over the course of the past month, outperforming the Medical sector's loss of 4.05% and the S&P 500's gain of 3.15%. The investment community will be paying close attent ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $64.11, demonstrating a -0.9% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.04%. Coming into today, shares of the company had gained 11.34% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 1.25%. The investment community will be closely monitoring the performance of Vi ...

An analyst waxed bullish on the company's leading pipeline program. Although Viking Therapeutics (VKTX 2.73%) is a busy company, on Monday its stock moved because of external news. A pundit reiterated his bullish take on the clinical-stage biotech, boosting sentiment on its shares and sending them nearly 3% higher in price. That was more than good enough to top the rising S&P 500 index, which closed the trading session up by 0.4%. An instant competitor Like many investors, Morgan Stanley analyst Michael Ulz ...

The company is in the spotlight for one of its programs, but it's got others that also have promise. One of the current stars of the biotech world is Viking Therapeutics (VKTX -1.11%), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if approved, would compete in the white-hot market for weight loss medications. While that's not the only product in the company's pipeline, it's the one that many investors have pinned their hopes on. Typically, for a ...